Ir para o conteúdo principal

United States Últimas notícias

Todas as matérias desta categoria, das mais recentes às mais antigas.

Grafa
Health

Harmony Biosciences wins FDA approval for WAKIX in pediatric cataplexy

Harmony Biosciences Holdings (NASDAQ:HRMY) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) to treat cataplexy in pediatric patients aged six years and older.

Leia mais: Harmony Biosciences wins FDA approval for WAKIX in pediatric cataplexy
Grafa
Industrials

SunCoke Energy posts FY adjusted EBITDA of $219.2M amid one-time charges

SunCoke Energy (NYSE:SXC) reported a full-year 2025 net loss attributable to SXC of $44.2 million, or $0.52 per diluted share, compared with prior-year performance, primarily due to unfavorable one-time items totaling $109.3 million pre-tax ($83.1 million net of tax).

Leia mais: SunCoke Energy posts FY adjusted EBITDA of $219.2M amid one-time charges
Grafa
Technology

Watsco achieves record gross margin of 28% in 2025, raises dividend 10%

Watsco (NYSE:WSO) posted full-year 2025 revenues of $7.24 billion, down 5% from the prior year, reflecting headwinds in equipment volumes offset partially by an 11% increase in average domestic selling prices and contributions from parts and supplies.

Leia mais: Watsco achieves record gross margin of 28% in 2025, raises dividend 10%
Grafa
Technology

Hillman Solutions delivers record 2025 sales of $1.55B, up 5.4%

Hillman Solutions (NASDAQ:HLMN) reported record full-year 2025 net sales of $1.55 billion, an increase of 5.4% from 2024, driven by strength across its fastener, keys, and protective solutions categories, as well as contributions from merchandising innovations and expanded retail partnerships.

Leia mais: Hillman Solutions delivers record 2025 sales of $1.55B, up 5.4%
Grafa
Health

Palatin fortifies balance sheet to fuel next-generation obesity drug trials

Palatin Technologies (NYSE:PTN) reported its fiscal second-quarter 2026 results on Tuesday, marking a critical operational pivot as the biopharmaceutical firm clears financial hurdles and prepares to enter the highly competitive clinical landscape for weight-loss therapies.

Leia mais: Palatin fortifies balance sheet to fuel next-generation obesity drug trials